Unlike their global counterparts,
the Indian pharmaceutical market — estimated at 400 billion Indian rupees (US $ 8 billion) in 2001 — is in a business climate of token R&D investment.
Not exact matches
Given rising competition in the generics space, Teva could also use the additional size to gain back
market share from
Indian manufacturers such as Sun
Pharmaceuticals.
The external
pharmaceutical companies will then have access to the
Indian patient population,
market, and clinical trial subjects with an unmatched volume, disease profile, and therapy - naïve status.
Quality control has not just been an issue for Ranbaxy, in fact other
Indian drugmakers have come under closer scrutiny as the FDA, the guardian of the world's most important
pharmaceuticals market, has increased its presence in the country, reflecting India's growing importance as a supplier to the United States.